PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Salient Surgical Technologies, Inc., a privately-held developer and innovator of advanced energy devices for use in surgical procedures, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the AQUAMANTYS bipolar sealer for use in blunt dissection. The company also recently received Japanese regulatory approval and European CE Mark clearance for commercial marketing of the device.
The new AQUAMANTYS device runs on Salient’s bipolar technology platform that uses proprietary TRANSCOLLATION® technology to enable surgeons to prevent and stop bleeding of soft tissue and bone during surgery. The new disposable sealer features cone-shaped electrodes that are designed to aid blunt dissection and provide hemostatic sealing across broad plains of tissue.
“We’ve incorporated Salient’s technology into our practice as of a result of its proven ability to help reduce blood loss and transfusion rates,” said T. Clark Gamblin, MD, MS, Chief of the Division of Surgical Oncology at the Medical College of Wisconsin. “In our experience, the new AQUAMANTYS bipolar electrode provides a safe and convenient means to achieve these clinical benefits during surgical oncology procedures, such as liver resections.”
About Salient Surgical Technologies
Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. The company’s AQUAMANTYS® System uses patented TRANSCOLLATION® technology, which provides hemostatic sealing of soft tissue and bone tissue at the surgical site. This technology has been used to optimize care for more than 500,000 patients undergoing orthopaedic reconstruction, spine, orthopaedic trauma and surgical oncology procedures.
